| Ytd | 80.53% | |
| 1y | 72.64% |
| Open | 7.48 | Prev Close | 7.46 | Low | 7.36 | High | 7.63 | Mkt Cap | 96.34M |
| Vol | 0.00 | Avg Vol | 433.19K | EPS | -2.94 | P/E | -2.55 | Forward P/E | -0.66 |
| Beta | 1.69 | Short Ratio | 2.42 | Inst. Own | 44.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.35 | 200-d Avg | 6.05 | 1yr Est | 33.60 |
DTIL News
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being high
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Cons
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Tra
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-q
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Friday, 469 companies hit new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
OnFriday, 143 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings fo
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quar
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.